Drug Name: Orserdu
Indications: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Active Ingredient: Elacestrant
Company: Stemline Therapeutics, Inc
Approval Date: 1/27/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf